Drugs / Surovatamig
Surovatamig
Trials 9 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT07201558 | Dec 2025 → Jun 2028 expected | rheumatoid arthritis, systemic lupus erythematosus | AstraZeneca | Recruiting | No outcome recorded |
| Phase 1 | NCT04594642 | Mar 2021 → Jun 2028 expected | follicular lymphoma, high grade B-cell lymphoma | AstraZeneca | Active not recruiting | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT06564038 | Jan 2025 → Jun 2029 expected | chronic lymphocytic leukemia/small lymphocytic lymphoma, large B-cell lymphoma, mantle cell lymphoma | AstraZeneca | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06137118 | Dec 2023 → Nov 2026 expected | B-cell acute lymphoblastic leukemia | AstraZeneca | Recruiting | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT07571746 | Mar 2026 → Apr 2028 expected | idiopathic membranous glomerulonephritis | AstraZeneca | Recruiting | No outcome recorded |
| Phase 2 | NCT06526793 | Nov 2024 → Nov 2027 expected | follicular lymphoma, large B-cell lymphoma | AstraZeneca | Recruiting | No outcome recorded |
| Phase 33 trials | ||||||
| Phase 3 | NCT07509151 | May 2026 → Aug 2031 expected | chronic lymphocytic leukemia/small lymphocytic lymphoma | AstraZeneca | Recruiting | No outcome recorded |
| Phase 3 | NCT07215585 | Nov 2025 → Jun 2030 expected | large B-cell lymphoma | AstraZeneca | Recruiting | No outcome recorded |
| Phase 3 | NCT06549595 | Aug 2024 → Nov 2031 expected | follicular lymphoma | AstraZeneca | Recruiting | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 10 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Surovatamig | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07509151 ↗ |
| Known as | AZD0486 | “Surovatamig (AZD0486) monotherapy” NCT06526793 ↗ |
| Known as | TNB-486 | ChEMBL registry synonym — accepted as the source's own label CHEMBL6068301 ↗ |
| Action | Deplete | “leading to T cell-mediated cytotoxicity of malignant B cells” NCT04594642 ↗ |
| Modality | Protein / enzyme biologic | “Surovatamig is a bispecific T-cell engager administered subcutaneously.” NCT07201558 ↗ |
| Route | Intravenous | “administered intravenously” NCT04594642 ↗ |